Truist raised the firm’s price target on Cytokinetics to $86 from $60 and keeps a Buy rating on the shares. Following a management conference call on Phase 3 SEQUOIA-HCM data, the analyst notes notes that the firm’s conviction around best-in-class potential for aficamten has been further strengthened. Truist is now modeling 2032 adjusted peak sales of $3.2B vs. $2.5B previously, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYTK:
- Here’s Why Cytokinetics (NASDAQ:CYTK) Stock Surged Yesterday
- Cytokinetics jumps 43% after reporting results of study of aficamten in HCM
- Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
- Cytokinetics reports topline results from SEQUOIA-HCM Phase 3 trial
- Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy